Dados B3 › CMIG4 × EGIE3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | CMIG4 | EGIE3 | year |
|---|---|---|---|
| ROE | 17.5% | 21.5% | 2025 |
| ROIC | 14.1% | 13.9% | 2025 |
| ROA | 7.7% | 5.4% | 2025 |
| Gross margin | 16.9% | 46.7% | 2025 |
| EBIT margin | 15.8% | 48.7% | 2025 |
| Net margin | 11.5% | 22.2% | 2025 |
| Net debt/EBITDA | 2.03x | 3.30x | 2025 |
| Current ratio | 1.00x | 1.12x | 2025 |
| Revenue growth (1y) | 7.4% | 14.6% | 2025 |
| Revenue growth (5y CAGR) | 11.1% | 1.0% | 2025 |
| Piotroski F-Score | 4/9 | 5/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | CMIG4 | EGIE3 | year |
|---|---|---|---|
| P/E | 7.12x | 14.21x | 2025 |
| P/B | 1.22x | 2.88x | 2025 |
| EV/EBITDA | 6.24x | 8.09x | 2025 |
| FCF yield | 8.6% | 4.3% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:42 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it